111
Participants
Start Date
September 30, 2005
Primary Completion Date
December 31, 2008
Study Completion Date
December 31, 2011
NY-ESO-1 ISCOMATRIX®
"100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.~Each patient will receive four intramuscular injections of NY-ESO-1 ISCOMATRIX® vaccine. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
ISCOMATRIX® adjuvant
"120 μg of ISCOMATRIX® adjuvant~Each patient will receive four intramuscular injections of ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
Sydney Melanoma Unit - Royal Prince Alfred Hospital, Camperdown
Newcastle Melanoma Unit - Newcastle Mater Misericordiae Hospital, Newcastle
Peter MacCallum Cancer Centre, East Melbourne
Austin Health (Ludwig Institute Oncology Unit), Heidelberg
Mater Medical Centre, Princess Alexandra Hospital, Woolloongabba
Sir Charles Gairdner Hospital, Nedlands
University of Auckland (Waitemata DHB), Auckland
University Hospital - Birmingham, Birmingham
Addenbrooke's Hospital, Cambridge
Western Infirmary, Glasgow
St Georges Hospital, London
Royal Marsden Hospital, London
Mount Vernon Hospital, Northwood
Weston Park Hospital, Sheffield
Southampton University Hospitals, Southampton
Lead Sponsor
Institute of Cancer Research, United Kingdom
OTHER
Ludwig Institute for Cancer Research
OTHER